Returns to the list on rising sales and profits at his privately held Intas Pharmaceuticals, in which Temasek and ChrysCapital are investors. The company, run by sons Nimish and Binish, acquired a biotech unit from Harsh Goenka's (No.75) RPG Life Sciences for $4 million. Intas is awaiting regulatory approval to launch a biosimilar version of an Amgen blockbuster cancer drug that boosts white blood cells. Sun Pharmaceuticals, controlled by fellow billionaire Dilip Shanghvi (No. 2), is reportedly eyeing the company as a takeover target.